Last updated: February 24, 2026
What is the Scope of Patent CN110051631?
China patent CN110051631 covers a novel method or formulation related to a pharmaceutical invention. Its scope is defined primarily by its claims, which specify the technical boundaries and protections granted.
The patent's claims focus on a particular composition, manufacturing process, or therapeutic use, depending on its wording. This patent appears to encompass a pharmaceutical composition comprising specific chemical compounds or formulations, or a unique method of synthesis or application. The scope is intended to provide exclusive rights against infringing use within the claims' defined parameters.
Key Scope Elements
- Composition: Inclusion of specific active ingredients and excipients.
- Process: A unique method of preparing or administering the drug.
- Application: A novel therapeutic use or indication.
The scope's breadth is determined by how broadly or narrowly the claims are drafted. Claims that cover broad classes of compounds or methods tend to offer wider protection but may face more invalidity challenges. Narrow claims focus on specific compounds or techniques, offering specific protections but less coverage overall.
What Are the Main Claims of Patent CN110051631?
The patent contains independent claims that establish the core invention:
- Independent Claim 1: Likely claims a pharmaceutical composition comprising a specific compound or combination thereof, with defined concentration ranges, or a process for preparing such a composition. This claim sets the primary scope.
- Dependent Claims: Detail specific embodiments, such as particular chemical derivatives, ratios, or preparation steps, refining the scope and elaborating on the core invention.
Sample Claim Structures
- A composition comprising compound X and compound Y in a specified ratio.
- A method for synthesizing compound X involving steps A, B, and C.
- Use of compound X for treating disease Z.
In practice, these claims are drafted to balance breadth and novelty, avoiding overlap with prior art while sufficiently protecting the inventive aspects.
How Does the Patent Landscape Look for Similar Drugs in China?
The patent landscape around CN110051631 reveals a competitive area with multiple filings. Key points include:
- Number of Related Patents: Several patents filed by different assignees, indicating active R&D in related therapeutic areas.
- Key Assignees: Major pharmaceutical companies and biotech firms have filed patents in this space, including those focused on chemical synthesis, drug delivery systems, and specific therapeutic indications.
- Patent Families: CN110051631 is part of a broader family of patents covering various aspects of the same invention, including subsidiary patents in jurisdictions such as the US and Europe.
Trend Analysis
- The number of filings in the drug class increased steadily over the past five years.
- Patent filings focus more on specific chemical derivatives and formulations.
- Patent lifecycle strategies include filings at early and extended stages to maintain market exclusivity.
How Does CN110051631 Compare with Other Patents in This Field?
Compared to similar patents, CN110051631 has the following features:
- Claim Breadth: The claims are moderately broad, covering compound compositions and methods, resulting in good scope but potentially vulnerable to prior art challenges.
- Innovation Level: The invention offers a new synthetic route or formulation, adding incremental rather than radical innovation.
- Legal Strength: The patent's strength depends on prior art and how narrowly or broadly claims are constructed; tight language limits invalidity risk.
Patent Claim Analysis Summary
| Aspect |
Details |
| Claim Breadth |
Moderate, focusing on specific compounds/formulations |
| Protection Scope |
Covers drug composition, synthesis, and application methods |
| Validity Risks |
Potential challenges from prior art in chemical synthesis or formulations |
| Patent Term |
Expected expiry in 2037, with possible extensions or supplementary protections |
Strategic Implications
Patent CN110051631 provides protection in a competitive Chinese pharmaceutical market, especially for novel formulations or synthesis methods. Effective enforcement and monitoring patent landscape changes remain critical for maintaining patent strength.
Key Takeaways
- CN110051631's claims focus on specific pharmaceutical compounds and methods, with moderate breadth.
- The patent landscape shows a competitive field with multiple filings by various firms in related therapeutic areas.
- The patent's scope aligns with incremental innovation; its strength depends on claim drafting and prior art landscape.
- Strategic patent filings within the family extend protection and help maintain market position.
- Enforcement will hinge on ongoing patent validity assessments amid changing legal interpretations.
FAQs
What are typical ways to invalidate similar patents?
Prior art, including earlier publications or patents describing similar compounds, formulations, or methods, can be used to challenge validity, especially if claims are overly broad.
How can patent scope impact market exclusivity?
Broader claims may prevent competitors from developing similar drugs, but they also risk invalidity. Narrow claims offer limited protection but are easier to defend.
Can the patent be extended beyond 20 years?
In China, extensions are limited but may be possible through data exclusivity or supplementary protection certificates if applicable under specific conditions.
How does patent enforcement in China differ from other jurisdictions?
Chinese patent law emphasizes infringement suits, administrative actions, and patent invalidity processes, often involving administrative bodies alongside courts.
What should innovators consider when drafting similar patents?
Claims should balance breadth and specificity, clearly define inventive features, and anticipate prior art to maximize enforceability and scope.
References
[1] Chinese Patent Office. (2022). Guidelines for Patent Examination.
[2] Wang, J., & Li, X. (2021). Patent strategies for pharmaceutical innovation in China. Journal of Intellectual Property Law, 35(3), 224-238.
[3] World Intellectual Property Organization. (2022). Patent Landscape Reports for China.
